[Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
The effect of the antiparkinsonian drug hemantane on various subtypes of dopamine receptors in the striatum of Wistar rats have been studied after subchronic administration of the drug in a single daily dose of 20 mg/kg (i.p.) over seven days. The receptor binding was studied using the striatum membranes isolated from the test rats decapitated after the last injection of the drug. A modulatory influence of hemantane on the D1, D2 and D3 type receptors was revealed. It was found that hemantane increased the density of the binding sites of D1 receptors and decreased the density of the binding sites of D2 and D3 receptors without changing their affinity to the selective ligands. These results indicate that the subchronic administration ofhemantane can lead to the functional rearrangement of the main subtypes of dopamine receptors in the rat striatum.
Abaimov
D A
DA
Zimin
I A
IA
Kovalev
G I
GI
D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology*; D008297:Male; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000819:agonists / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000819:agonists / Q000378:metabolism*
D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C526127:hemantane; D000218:Adamantane